These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 29793275)

  • 21. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How will GINA influence participation in pharmacogenomics research and clinical testing?
    Dressler LG; Terry SF
    Clin Pharmacol Ther; 2009 Nov; 86(5):472-5. PubMed ID: 19844223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ethics and policy perspectives on personalized medicine in the post-genomic era.
    Landon MR
    J Biolaw Bus; 2005; 8(3):28-36. PubMed ID: 16459425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychiatric pharmacists' perception on the use of pharmacogenomic testing in the mental health population.
    Shishko I; Almeida K; Silvia RJ; Tataronis GR
    Pharmacogenomics; 2015; 16(9):949-58. PubMed ID: 26100610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic testing insurance coverage trends: a review of publicly available policies from the largest US payers.
    Graf MD; Needham DF; Teed N; Brown T
    Per Med; 2013 May; 10(3):235-243. PubMed ID: 29768740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implementation of a pharmacogenomics service in a community pharmacy.
    Ferreri SP; Greco AJ; Michaels NM; O'Connor SK; Chater RW; Viera AJ; Faruki H; McLeod HL; Roederer MW
    J Am Pharm Assoc (2003); 2014; 54(2):172-80. PubMed ID: 24632932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Institutional profile: The Carney Centre for Pharmacogenomics: a New Zealand focus for personalized medicine research.
    Kennedy MA; Joyce PR; Begg EJ
    Pharmacogenomics; 2012 Jun; 13(8):865-8. PubMed ID: 22676191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NAVAGATE: a rubric to move from pharmacogenomics science to pharmacogenomics practice.
    Roederer MW
    Pharmacogenomics; 2012 Aug; 13(11):1307-13. PubMed ID: 22920399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.
    Altar CA; Carhart JM; Allen JD; Hall-Flavin DK; Dechairo BM; Winner JG
    Pharmacogenomics J; 2015 Oct; 15(5):443-51. PubMed ID: 25686762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [From pharmacogenetics to pharmacogenomics: the start of a new era of personalized medicine in nephrology].
    Zaza G; Granata S; Mangino M; Grandaliano G; Schena FP
    G Ital Nefrol; 2010; 27(4):353-66. PubMed ID: 20672232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenomic knowledge representation, reasoning and genome-based clinical decision support based on OWL 2 DL ontologies.
    Samwald M; Miñarro Giménez JA; Boyce RD; Freimuth RR; Adlassnig KP; Dumontier M
    BMC Med Inform Decis Mak; 2015 Feb; 15():12. PubMed ID: 25880555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relevance of pharmacogenomics for developing countries in Europe.
    Mitropoulos K; Johnson L; Vozikis A; Patrinos GP
    Drug Metabol Drug Interact; 2011; 26(4):143-6. PubMed ID: 22017487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.
    Squassina A; Manchia M; Manolopoulos VG; Artac M; Lappa-Manakou C; Karkabouna S; Mitropoulos K; Del Zompo M; Patrinos GP
    Pharmacogenomics; 2010 Aug; 11(8):1149-67. PubMed ID: 20712531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenomics: the promise of personalized medicine for CNS disorders.
    de Leon J
    Neuropsychopharmacology; 2009 Jan; 34(1):159-72. PubMed ID: 18800072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory agency consideration of pharmacogenomics.
    Pendergast MK
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Personalized medicine: reality and reality checks.
    Leeder JS; Spielberg SP
    Ann Pharmacother; 2009 May; 43(5):963-6. PubMed ID: 19417116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.
    Arbitrio M; Di Martino MT; Scionti F; Agapito G; Guzzi PH; Cannataro M; Tassone P; Tagliaferri P
    Oncotarget; 2016 Aug; 7(33):54028-54050. PubMed ID: 27304055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Translating pharmacogenomics: challenges on the road to the clinic.
    Swen JJ; Huizinga TW; Gelderblom H; de Vries EG; Assendelft WJ; Kirchheiner J; Guchelaar HJ
    PLoS Med; 2007 Aug; 4(8):e209. PubMed ID: 17696640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolving provider payment models and patient access to innovative medical technology.
    Long G; Mortimer R; Sanzenbacher G
    J Med Econ; 2014 Dec; 17(12):883-93. PubMed ID: 25221929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A hub for bench-to-bedside pharmacogenomic-based research.
    Voora D; Ginsburg GS
    Pharmacogenomics; 2011 Aug; 12(8):1095-8. PubMed ID: 21843063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.